Polymyositis: 2026 so far

Course-over-time data emerged, linking antibodies and relapse risk.

New real-world cohorts in the months covered described what treatment paths looked like over time. Complete remission after initial treatment was achievable for many people, but relapse still occurred in a substantial subset. In one retrospective cohort (a study looking back at existing records), anti-ARS antibody positivity was linked to higher relapse risk, while achieving complete remission was linked to lower relapse risk. The report also compared relapse regimens and did not find more severe adverse events with the lowest second-relapse approach. Separately, a small report of checkpoint inhibitors (cancer immunotherapy drugs that can activate the immune system) in people with pre-existing inflammatory myopathy observed a flare in one person while most did not flare, showing that responses can vary in this special treatment context. These findings support planning follow-up with both remission and relapse in mind, and they show how antibody status is sometimes used to help interpret risk in observational data.

Research covered in: August 2026

A mechanistic blood signal was tied to later rituximab response.

A new single-center cohort suggested that early, deeper depletion of specific B-cell subsets (types of immune cells measured in detail) after rituximab was associated with being classified as a responder months later. A simpler conventional B-cell cutoff did not relate to response. This shifted monitoring from just 'B cells are low' to 'which B-cell subsets drop, and how completely,' but it relied on detailed testing not described as routine. The study was observational and does not prove the blood changes cause improvement. This points to a possible future way to interpret response to B-cell-targeting therapy, but it is not yet established for routine care.

Research covered in: August 2026

Routine-care reporting highlighted day-to-day outcomes after Acthar.

A physician-reported chart review added a new, descriptive snapshot of Acthar Gel use in dermatomyositis/polymyositis, focusing on everyday outcomes rather than only lab measures. Physicians reported improved overall health status after Acthar Gel for most patients in that dataset. They also described goals including improving symptoms, strength, physical function, and reducing corticosteroid use. Because there was no matched comparison group, the report cannot separate medication effects from other factors. This kind of real-world reporting is increasingly describing treatment impact in terms of pain, function, and steroid burden, while still not proving comparative effectiveness.

Research covered in: June 2026

Risk stratification expanded from models to acute-hospital predictors.

In the months covered, lung monitoring moved toward more specific risk signals. A retrospective model combining CT features (findings on a CT scan, a detailed type of imaging) with anti-MDA5 status separated near-term progression risk groups. Later work linked quantitative (computer-scored) CT burden and fibrosis (lung scarring) to lung function and survival in a large cohort. In the most acute setting, a hospital study of sudden ILD worsening (interstitial lung disease, scarring/inflammation in the lungs) in polymyositis/dermatomyositis reported substantial in-hospital mortality. It found low CD4 counts (a type of immune cell count) as the strongest marker linked to higher in-hospital death risk, with additional warning signs (e.g., pleural effusion, higher neutrophil percentage, higher CRP) and higher risk in anti-MDA5-positive patients. These are observational findings and do not test whether acting on the markers changes outcomes. Still, they show that ILD risk is increasingly described using combined markers and objective imaging measures, and that acute hospital flares had identifiable high-risk lab patterns in one cohort.

Research covered in: February 2026, March 2026, July 2026, September 2026

Multiple datasets quantified non-muscle burdens and linked them to outcomes.

So far in 2026, multiple studies quantified common, high-impact complications beyond muscle weakness. Dysphagia (trouble swallowing) was frequently discussed. Instrumental swallowing tests (camera- or sensor-based swallowing studies) detected it more often than bedside evaluation, and observational cohorts linked dysphagia to specific antibody and clinical patterns. Falls and fractures were reported as common in a large survey. A separate clinic cohort reported thyroid disorders were common and associated with esophagus involvement, osteoporosis/fragility fractures, and worse bodily pain scores. Infections were repeatedly highlighted as a major risk area in inflammatory myositis datasets, including a meta-analysis (a study combining results across studies) reporting infections in a substantial minority. A large cohort also reported higher influenza-related hospitalization (and limited-event estimates of higher short-term death) in polymyositis/dermatomyositis versus matched controls. Together, these findings show that day-to-day burden and safety risks are increasingly being measured and linked to identifiable patterns, even though most evidence remains observational and does not establish which interventions change these outcomes.

Research covered in: February 2026, March 2026, April 2026, May 2026, September 2026